<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04873206</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-04-29</org_study_id>
    <nct_id>NCT04873206</nct_id>
  </id_info>
  <brief_title>Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies</brief_title>
  <official_title>Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of&#xD;
      such progression is not determined. there a need to detect biological markers that can help&#xD;
      in detecting high risk cases of patients with endometrial hyperplasia that may progress to&#xD;
      endometrial adenocarcinoma. PTEN is a tumor suppressor gene that inhibit cell migration,&#xD;
      proliferation and may induce apoptosis in damaged cells. variable expression of PTEN in&#xD;
      functional, hyperplastic and neoplastic endometrial tissues may be of great help in detecting&#xD;
      cases of hyperplasia that may progress to endometrial adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial carcinoma is the most common invasive neoplasm of female genital system. there&#xD;
      are two types of endometrial carcinoma, type I represents more than 80% of all cases and&#xD;
      almost always preceded by endometrial hyperplasia. However, the malignant potential of&#xD;
      endometrial hyperplasia to carcinoma is highly variable and subjected to interobserver&#xD;
      variations. so, there is a compelling need to determine a prognostic biological marker that&#xD;
      can help in detecting cases of endometrial hyperplasia that may progress to endometrial&#xD;
      adenocarcinoma. PTEN is a tumor suppressor gene. it inhibits cell proliferation and&#xD;
      migration. PTEN may induce apoptosis in damaged cells. decrease expression of PTEN has been&#xD;
      detected in different human neoplasms as melanoma, breast and ovarian carcinomas.&#xD;
&#xD;
      The aim of this study is to investigate the expression of PTEN (by immunohistochemistry) in&#xD;
      some endometrial biological conditions as endometrial hyperplasia and primary endometrial&#xD;
      adenocarcinoma specimens, and compare such expression to PTEN expression in normal&#xD;
      functional/ cyclical endometrial tissue specimens.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Investigating the Immunohistochemical Expression of PTEN in Different Endometrial Biopsies.</measure>
    <time_frame>June, 2021</time_frame>
    <description>cases of primary endometrial carcinoma and complex endometrial hyperplasia should express mutant form of PTEN compared to functional and simple hyperplastic endometrial tissues.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Endometrial Hyperplasia</condition>
  <condition>Endometrial Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Functional/ Cyclical Endometrial group.</arm_group_label>
    <description>cases of normal endometrium will be obtained from hystrectomy specimens done for causes other than hyperplasia or adenocarcinoma, for example; uterine fibroids, uterine prolapse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyperplastic Endometrial group.</arm_group_label>
    <description>cases of endometrial hyperplasia obtained by D&amp;C or hystrectomy will be stained by H&amp;E stain and categorized into typical or atypical hyperplasia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary Endometrial Adenocarcinoma group.</arm_group_label>
    <description>cases of primary endometrial adenocarcinoma obtained by D&amp;C or hystrectomy operations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routine stain by H&amp;E.</intervention_name>
    <description>formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.</description>
    <arm_group_label>Functional/ Cyclical Endometrial group.</arm_group_label>
    <arm_group_label>Hyperplastic Endometrial group.</arm_group_label>
    <arm_group_label>Primary Endometrial Adenocarcinoma group.</arm_group_label>
    <other_name>Immunohistochemistry.</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      specimens fixed in Formalin and embedded in Parraffin&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        endometrial specimens and hystrectomy operations will be done in Gyn&amp;Obs Department of&#xD;
        Sohag University Hospital and will be prepared in formalin-fixed, Parraffin-embedded&#xD;
        blocks. endometrial blocks will be sectioned and stained by H&amp;E stain. from the same&#xD;
        blocks, corresponding tissue sections will be staine immunohistochemically by anti-human&#xD;
        PTEN antibodies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all cases of endometrial biopsies and hystrectomy specimens diagnosed as endometrial&#xD;
             hyperplasia and/or primary endometrial adenocarcinoma.&#xD;
&#xD;
          -  all cases of normal endometrium obtained from hystrectomy specimens due to other&#xD;
             pathological conditions as prolapsed uteri, uterine leiomyoma and adenomyosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  autolysed samples, very tiny specimens cervical tissues and specimens with&#xD;
             histological picture of endometritis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maisa H Mohammed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>a lecturer of pathology, Sohag faculty of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maisa Hashem Mohammed</name>
      <address>
        <city>Sohag</city>
        <zip>82524</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Maisa Hashem Mohammed</investigator_full_name>
    <investigator_title>lecturer of pathology</investigator_title>
  </responsible_party>
  <keyword>PTEN.</keyword>
  <keyword>Endometrial Hyperplasia.</keyword>
  <keyword>Endometrial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

